Trial reportWorld journal of gastroenterology2004
Abnormal function of platelets and role of angelica sinensis in patients with ulcerative colitis.
Trial report in World journal of gastroenterology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Abnormal platelet parameters in inflammatory bowel disease: a systematic review and meta-analysis.BMC gastroenterology · 2024Pooled it
- On the use of herbal medicines in management of inflammatory bowel diseases: a systematic review of animal and human studies.Digestive diseases and sciences · 2009Pooled it
- Connecting the Dots Between Pharmacokinetics, Inflammatory Biomarkers, and Mucosal Healing in Patients on Infliximab with Inflammatory Bowel Disease.Pharmaceutics · 2026Article
- Review
- Research Progress on the Immunomodulatory Effects by Dang Gui (Molecules (Basel, Switzerland) · 2026Review
- Identification and validation of platelet activation-related signatures in ulcerative colitis: a study based on machine learning and single-cell transcriptomic analysis.Frontiers in immunology · 2026Article
- Acquired platelet disorders.Frontiers in medicine · 2025Review
- Biomarkers in inflammatory bowel diseases: insight into diagnosis, prognosis and treatment.Gastroenterology and hepatology from bed to bench · 2017Review
- Coagulation parameters in inflammatory bowel disease.International journal of clinical and experimental medicine · 2014Article
- Biomarkers of inflammatory bowel disease.Disease markers · 2014Review
- Relationship and significance between anti-beta2-glycoprotein I antibodies and platelet activation state in patients with ulcerative colitis.World journal of gastroenterology · 2008Article
- Higher platelet P-selectin in male patients with inflammatory bowel disease compared to healthy males.World journal of gastroenterology · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo explore the abnormal function of platelets and the role of angelica sinensis injection (ASI) in patients with ulcerative colitis (UC).
methodsIn 39 patients with active UC, 25 patients with remissive UC and 30 healthy people, alpha-granule membrane protein (GMP-140) and thromboxane B(2) (TXB(2)) were detected by means of ELISA, 6-keto-PGF(1a) was detected by radioimmunoassay, platelet count (PC) and 1 min platelet aggregation rate (1 min PAR) were detected by blood automatic tester and platelet aggregation tester respectively, and von Willebrand factor related antigen (vWF:Ag) was detected by the means of monoclonal -ELISA. The 64 patients with UC were divided into two therapy groups. After routine treatment and angelica sinensis injection (ASI) + routine treatment respectively for 3 weeks, all these parameters were also detected.
resultsThe PC, 1 min PAR and levels of GMP-140, TXB(2), and vWF:Ag in active UC were significantly higher than those in remissive UC and normal controls (P<0.05-0.01).Meanwhile, 1 min PAR and levels of GMP-140, TXB(2), and vWF:Ag in remissive UC were still significantly higher than those in normal controls (P<0.05). Furthermore, 6-keto-PGF(1a) level in active and remissive UC was remarkably lower than that in normal control (P<0.05-0.01). These parameters except 6-keto-PGF(1a) were significantly improved after the treatment in ASI therapy group (P<0.05-0.01), whereas they all were little changed in routine therapy group (P>0.05).
conclusionPlatelets can be significantly activated in UC, which might be related with vascular endothelium injury and imbalance between TXB(2) and 6-keto-PGF(1a) in blood. ASI can significantly inhibit platelet activation, relieve vascular endothelial cell injury, and improve microcirculation in UC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.